Vimarsana
Biggest News Aggregation in the World

Page 5 - Celcuity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Celcuity Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Celcuity Inc Today - Breaking & Trending Today

Commodore Capital LP Raises Holdings in Celcuity Inc. (NASDAQ:CELC) - Vimarsana News

Commodore Capital LP Raises Holdings in Celcuity Inc. (NASDAQ:CELC)

Commodore Capital LP lifted its holdings in shares of Celcuity Inc. (NASDAQ:CELC – Free Report) by 3.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,444,141 shares of the company’s stock after buying an additional 53,369 shares during the period. […]

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer ... - Vimarsana News

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer ...

MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib

Celcuity Inc. (NASDAQ:CELC) Short Interest Update - Vimarsana News

Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC – Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 366,900 shares, a drop of 10.6% from the October 31st total of 410,300 shares. Based on an average trading volume of 61,300 shares, the […]

Celcuity to Participate in the 6th Annual Evercore ISI - Vimarsana News

Celcuity to Participate in the 6th Annual Evercore ISI

MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted...

Research Analysts' Updated EPS Estimates for November 13th (AADI, ANNX, ARMK, CELC, CRK, ENZ, FUN, MDB, MERC, NSIT) - Vimarsana News

Research Analysts' Updated EPS Estimates for November 13th (AADI, ANNX, ARMK, CELC, CRK, ENZ, FUN, MDB, MERC, NSIT)

Research Analysts’ updated eps estimates for Monday, November 13th: Aadi Bioscience (NASDAQ:AADI) had its price target reduced by HC Wainwright from $45.00 to $36.00. HC Wainwright currently has a buy rating on the stock. Annexon (NASDAQ:ANNX) had its price target trimmed by Needham & Company LLC from $24.00 to $16.00. They currently have a buy […]